Cardiovascular Drugs Practice Questions

Q: Which of the following is FALSE about Aliskiren?

It is a p-glycoprotein inhibitor. **Explanation:** **Aliskiren** is the first orally active **Direct Renin Inhibitor (DRI)**. Understanding its mechanism and pharmacokinetics is crucial for NEET-PG. **Why Option C is the correct (False) statement:** Aliskiren is actually a **substrate** of P-glycoprotein (P-gp), not an inhibitor. Drugs that inhibit P-gp (like Ketoconazole, Cyclosporine, or Verapamil) can significantly increase the plasma concentration of Aliskiren, leading to toxicity. It does not inhibit the transporter itself. **Analysis of Incorrect Options:** * **Option A (True):** Aliskiren is the only clinically used **oral** direct renin inhibitor. It has low bioavailability (~2.5%), which is further reduced by high-fat meals. * **Option B (True):** Like ACE inhibitors and ARBs, Aliskiren reduces Aldosterone secretion. This leads to potassium retention, potentially causing **hyperkalemia**, especially when used in patients with renal impairment or those taking potassium-sparing diuretics. * **Option D (True):** This is its primary mechanism of action. By binding to the active site of Renin, it prevents the rate-limiting step of the RAAS cascade: the conversion of **Angiotensinogen to Angiotensin I**. **High-Yield Clinical Pearls for NEET-PG:** * **Contraindication:** Aliskiren is strictly contraindicated in **pregnancy** (teratogenic) and should not be combined with ACE inhibitors or ARBs in patients with **Diabetes Mellitus** due to increased risk of stroke and renal damage (ALTITUDE trial). * **Effect on PRA:** Unlike ACE inhibitors/ARBs which increase Plasma Renin Activity (PRA) via feedback, Aliskiren **decreases PRA**. * **Side Effects:** Apart from hyperkalemia, it can cause GI disturbances like **diarrhea** (at high doses) and angioedema (rare).

Q: Trimetazidine is used for which of the following conditions?

Angina. **Explanation:** **Trimetazidine** is a unique anti-anginal agent classified as a **pFOX (partial Fatty Acid Oxidation) inhibitor**. 1. **Why Angina is Correct:** Trimetazidine acts as a **metabolic modulator**. It inhibits the enzyme **3-ketoacyl-CoA thiolase (3-KAT)**, which shifts the myocardial metabolism from fatty acid oxidation to **glucose oxidation**. Since glucose oxidation requires less oxygen to produce the same amount of ATP compared to fatty acids, the drug improves myocardial energy efficiency. This protects the heart from ischemic injury without affecting heart rate or blood pressure, making it an effective add-on therapy for **Stable Angina Pectoris**. 2. **Why Other Options are Incorrect:** * **Hypertension:** Trimetazidine has no vasodilator properties and does not affect systemic vascular resistance; hence, it is not used for hypertension. * **CHF:** While metabolic support is beneficial, Trimetazidine is not a primary treatment for CHF. Standard therapy involves ACE inhibitors, Beta-blockers, and Diuretics. * **Arrhythmia:** It does not block ion channels (Sodium, Potassium, or Calcium) and thus lacks anti-arrhythmic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits 3-KAT enzyme → Shifts metabolism to glucose → Preserves ATP levels during ischemia. * **Hemodynamics:** It is a "pure" metabolic agent; it does **not** alter heart rate, blood pressure, or double product. * **Side Effects:** Can cause **Parkinsonian symptoms** (tremors, rigidity) and gait disturbances; it is contraindicated in patients with Parkinson’s disease. * **Similar Drug:** **Ranolazine** also acts on myocardial metabolism but primarily works by inhibiting the **late sodium current ($I_{Na}$)**.

Q: Which of the following drugs can increase the calcium sensitivity of myocytes?

Levosimendan. ### Explanation **Correct Option: B. Levosimendan** Levosimendan belongs to a class of drugs known as **Calcium Sensitizers**. It exerts its positive inotropic effect by binding to **Troponin C** in a calcium-dependent manner. This stabilizes the calcium-induced conformational change in the troponin complex, increasing the sensitivity of myofilaments to existing calcium without increasing the actual intracellular calcium concentration. Levosimendan has been approved for use in acute failure in Europe and has shown noninferiority against dobutamine [1]. This is clinically significant because it enhances myocardial contractility without increasing myocardial oxygen demand or causing arrhythmias associated with calcium overload. Additionally, it acts as a vasodilator by opening ATP-sensitive potassium channels. **Incorrect Options:** * **A. Omapatrilat:** This is a Vasopeptidase inhibitor that inhibits both Neprilysin and ACE. It was developed for hypertension and heart failure but is not a calcium sensitizer. * **C. Milrinone:** This is a **PDE-3 inhibitor**. It increases cAMP levels, which leads to an *increase* in intracellular calcium levels in myocytes [2]. While it is an inodilator, its mechanism is distinct from calcium sensitization. * **D. Sacubitril:** This is a **Neprilysin inhibitor** used in combination with Valsartan (ARNI) for heart failure [3]. It prevents the degradation of natriuretic peptides but has no direct effect on myocyte calcium sensitivity. **High-Yield Facts for NEET-PG:** * **Levosimendan Triple Action:** 1. Inotropy (Troponin C binding), 2. Vasodilation ($K_{ATP}$ channel opening), 3. Cardioprotection (mitochondrial $K_{ATP}$ channels). * **Advantage:** Unlike Dobutamine or Milrinone, Levosimendan does not increase the risk of calcium-induced arrhythmias. * **Pimobendan:** Another calcium sensitizer often mentioned in this category. * **Clinical Use:** Primarily used in acute decompensated heart failure.

Q: Which anti-androgen is used in heart failure?

Spironolactone. **Explanation:** **Spironolactone** is the correct answer because it is a **Mineralocorticoid Receptor Antagonist (MRA)**. While primarily used in heart failure to block the deleterious effects of aldosterone on the myocardium (preventing cardiac fibrosis and remodeling), it is chemically a steroid derivative with significant **anti-androgenic properties**. It acts as a competitive antagonist at the androgen receptor and inhibits 17α-hydroxylase, leading to side effects like gynecomastia and decreased libido, which are high-yield clinical markers for this drug. **Analysis of Options:** * **A. Carvedilol:** A non-selective beta-blocker with alpha-1 blocking activity. While it is a cornerstone in heart failure management (reducing mortality), it has no anti-androgenic activity. * **B. Sampatrilat:** A dual inhibitor of Angiotensin-Converting Enzyme (ACE) and Neutral Endopeptidase (NEP). It was studied for heart failure and hypertension but is not classified as an anti-androgen. * **D. Abiraterone:** A potent anti-androgen (CYP17 inhibitor) used in metastatic castration-resistant prostate cancer. It is **not** used to treat heart failure; in fact, it can cause fluid retention and hypertension due to mineralocorticoid excess. **High-Yield Clinical Pearls for NEET-PG:** * **RALES Trial:** Demonstrated that Spironolactone reduces mortality in NYHA Class III and IV heart failure. * **Eplerenone:** A more selective MRA with fewer anti-androgenic side effects (less gynecomastia) compared to Spironolactone. * **Potassium Sparing:** Both are potassium-sparing diuretics; the most critical side effect to monitor is **hyperkalemia**, especially when combined with ACE inhibitors or ARBs.

Q: Which of the following drug classes has both anti-arrhythmic and anti-anginal properties?

Beta blockers. **Explanation:** **Beta-blockers (Option A)** are the correct choice because they possess dual therapeutic utility in managing both arrhythmias and angina pectoris. * **Anti-anginal mechanism:** They reduce myocardial oxygen demand by decreasing heart rate (negative chronotropy), blood pressure, and myocardial contractility (negative inotropy). This increases diastolic perfusion time, improving coronary blood flow. * **Anti-arrhythmic mechanism:** Classified as **Vaughan-Williams Class II** anti-arrhythmics, they block sympathetic stimulation of the heart. This decreases the slope of Phase 4 depolarization in SA/AV nodes, thereby suppressing automaticity and slowing AV conduction. **Why other options are incorrect:** * **Nitrates (Option B):** These are potent vasodilators used primarily for angina (reducing preload). They have no direct anti-arrhythmic properties and can actually cause reflex tachycardia, which may worsen certain arrhythmias. * **Rho-kinase inhibitors (Option C):** (e.g., Fasudil) These are used primarily in cerebral vasospasm or pulmonary hypertension. They do not have established roles in treating cardiac arrhythmias. * **Potassium channel openers (Option D):** (e.g., Nicorandil) These act as vasodilators for angina. While they affect potassium channels, they do not function as Class III anti-arrhythmics (which are potassium channel *blockers*). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Beta-blockers are the first-line treatment for chronic stable angina and for rate control in atrial fibrillation. * **Post-MI:** They are the only anti-arrhythmics proven to reduce mortality in post-myocardial infarction patients. * **Calcium Channel Blockers (Verapamil/Diltiazem):** These are the other major class that also possess both anti-anginal and anti-arrhythmic (Class IV) properties.

Q: Pulmonary fibrosis occurs most commonly due to which of the following drugs?

Amiodarone. **Explanation:** **Amiodarone** is a Class III antiarrhythmic drug known for its high iodine content and long half-life. **Pulmonary toxicity** is its most serious adverse effect, occurring in approximately 5–10% of patients. The underlying mechanism involves both direct cellular toxicity and an indirect inflammatory response (phospholipidosis), where lipids accumulate within alveolar macrophages. This leads to chronic interstitial inflammation and, ultimately, **irreversible pulmonary fibrosis**. Risk factors include a cumulative dose, older age, and pre-existing lung disease. **Analysis of Incorrect Options:** * **Clindamycin (A):** A lincosamide antibiotic primarily associated with gastrointestinal side effects, most notably *Clostridioides difficile*-associated pseudomembranous colitis. * **Nikkomycin (C):** An experimental antifungal agent that inhibits chitin synthesis; it is not associated with pulmonary fibrosis. * **Kanamycin (D):** An aminoglycoside antibiotic. Its primary toxicities are ototoxicity (vestibulocochlear nerve damage) and nephrotoxicity, not pulmonary fibrosis. **High-Yield Clinical Pearls for NEET-PG:** * **Other drugs causing Pulmonary Fibrosis:** Remember the mnemonic **"B-B-M-A-T"**: **B**leomycin (most common chemotherapy cause), **B**usulfan, **M**ethotrexate, **A**miodarone, and **T**oxic Nitrofurantoin. * **Monitoring:** Patients on chronic Amiodarone therapy require baseline and periodic **Chest X-rays** and **Pulmonary Function Tests (PFTs)**. * **Amiodarone Side Effects:** Think of "6 Ps": **P**ulmonary fibrosis, **P**rolonged QT, **P**hotodermatitis (Blue-gray skin), **P**eripheral neuropathy, **P**hotophobia (corneal microdeposits), and **P**erturbed thyroid (Hypo/Hyperthyroidism).

Q: Which one of the following is not an adverse effect of ACE inhibitors?

Hypokalemia. **Explanation:** The correct answer is **Hypokalemia**. ACE inhibitors (ACEIs) actually cause **Hyperkalemia**, not hypokalemia. **Mechanism of Action & Correct Option:** ACE inhibitors block the conversion of Angiotensin I to Angiotensin II. Since Angiotensin II is a potent stimulator of **aldosterone** secretion from the adrenal cortex, its inhibition leads to decreased aldosterone levels. Aldosterone normally promotes sodium/water retention and potassium excretion in the distal tubules. Reduced aldosterone results in potassium retention, leading to **hyperkalemia**. This is a high-yield point for NEET-PG, especially when ACEIs are combined with potassium-sparing diuretics or in patients with renal impairment. **Analysis of Incorrect Options:** * **Cough (A):** This is the most common side effect (dry, irritating cough). It is caused by the accumulation of **bradykinin** and substance P in the lungs, as ACE is the enzyme responsible for their degradation. * **Angioneurotic edema (C):** A rare but life-threatening side effect also attributed to increased bradykinin levels. It involves swelling of the lips, tongue, and larynx. * **Skin rash (D):** Common with ACEIs, particularly **Captopril**, often due to its sulfhydryl group. **NEET-PG High-Yield Pearls:** * **Teratogenicity:** ACEIs are contraindicated in pregnancy as they cause fetal renal anomalies (Hypocalvaria). * **First-dose hypotension:** Common in patients on diuretics; start with a low dose at bedtime. * **Bilateral Renal Artery Stenosis:** ACEIs are strictly contraindicated as they can precipitate acute renal failure by reducing efferent arteriolar tone. * **Mnemonic for ACEI side effects (CAPTOPRIL):** **C**ough, **A**ngioedema, **P**roteinuria, **T**aste changes, **O**ther (rash), **P**regnancy contraindication, **R**enal artery stenosis contraindication, **I**ncreased potassium (**Hyperkalemia**), **L**ow BP (First-dose hypotension).

Q: Which drug is used in the management of AV block?

Isoprenaline. **Explanation:** **Correct Option: A. Isoprenaline** Isoprenaline is a potent, non-selective **$̒$-adrenergic agonist** ($̒_1$ and $̒_2$). Its action on $̒_1$ receptors in the heart results in significant positive chronotropic (increased heart rate) and dromotropic (increased conduction velocity) effects [1]. By enhancing conduction through the AV node and increasing the idioventricular rate, it is used as a temporary pharmacological measure to manage high-grade AV block and symptomatic bradycardia until a permanent pacemaker can be inserted [1], [4]. **Analysis of Incorrect Options:** * **B. Dopamine:** While Dopamine has $̒_1$ effects at moderate doses, it is primarily used for cardiogenic or septic shock due to its $̡_1$ (vasoconstriction) and dopaminergic (renal vasodilation) properties [3]. It is not the first-line choice specifically for reversing AV block. * **C. Atropine:** Atropine is an anticholinergic used for sinus bradycardia [2]. While it can improve AV conduction by blocking vagal tone, it is often ineffective in **Type II Second-degree or Third-degree (Complete) AV blocks**, especially if the block is infra-nodal (within the Bundle of His). * **D. Disopyramide:** This is a Class IA antiarrhythmic. It actually **prolongs** the PR interval and can worsen AV block due to its sodium channel blocking properties, making it contraindicated in this condition. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For acute symptomatic bradycardia/AV block, **Atropine** is usually the initial drug [2], but **Isoprenaline** or **Adrenaline** infusions are preferred if Atropine fails or in cases of high-grade distal blocks [4]. * **Definitive Treatment:** The definitive management for chronic or high-grade AV block is a **Permanent Pacemaker**. * **Isoprenaline Side Effects:** It can cause palpitations, tremors, and may worsen myocardial ischemia by increasing oxygen demand [1].

Q: In shock, what effect does dopamine, in renal doses, have on renal vasculature?

Dilatation of renal vasculature. **Explanation:** Dopamine is a unique catecholamine because its pharmacological effects are strictly **dose-dependent**. Understanding these dose ranges is a high-yield concept for NEET-PG. **1. Why the correct answer is right:** At **low doses (0.5–2 µg/kg/min)**, often referred to as the **"Renal Dose,"** dopamine selectively stimulates **D1 receptors** located in the renal, mesenteric, and coronary vascular beds. Activation of D1 receptors leads to an increase in intracellular cAMP, resulting in **vasodilation of the renal vasculature**. This increases renal blood flow and glomerular filtration rate (GFR), promoting diuresis and natriuresis. **2. Why the incorrect options are wrong:** * **Option A:** While dopamine can decrease total peripheral resistance at intermediate doses (via β2 stimulation), "renal dose" specifically targets D1 receptors for localized renal vasodilation, not systemic reduction in resistance. * **Option B:** Constriction occurs at **high doses (>10 µg/kg/min)** due to **α1 receptor** stimulation. This causes systemic vasoconstriction, which can actually decrease renal perfusion. * **Option D:** Increase in cardiac output is the primary effect of **intermediate doses (2–10 µg/kg/min)**, where **β1 receptor** stimulation increases myocardial contractility (inotropy) and heart rate (chronotropy). **NEET-PG High-Yield Pearls:** * **Dopamine Dose Summary:** Low (D1: Vasodilation) → Mid (β1: Inotropy) → High (α1: Vasoconstriction). * **Fenoldopam:** A selective D1 agonist used in hypertensive emergencies to maintain renal perfusion. * **Clinical Note:** Current guidelines (like SSC) suggest that "low-dose dopamine" does not significantly improve outcomes in acute renal failure compared to placebo, though it remains a classic pharmacological concept for exams.

Question 1

Which of the following is FALSE about Aliskiren?

Accepted Answer

It is a p-glycoprotein inhibitor

Answer

It is an oral renin inhibitor

Answer

It can result in hyperkalemia

Answer

It blocks the conversion of angiotensinogen to Angiotensin I

Question 2

Trimetazidine is used for which of the following conditions?

Accepted Answer

Angina

Answer

Hypertension

Answer

Congestive Heart Failure (CHF)

Answer

Arrhythmia

Question 3

Which of the following drugs can increase the calcium sensitivity of myocytes?

Accepted Answer

Levosimendan

Answer

Omapatrilat

Answer

Milrinone

Answer

Sacubitril

Question 4

Which anti-androgen is used in heart failure?

Accepted Answer

Spironolactone

Answer

Carvedilol

Answer

Sampatrilat

Answer

Abiraterone

Question 5

What is the typical time taken for digitalization in cardiac therapy?

Accepted Answer

5 days

Answer

36 hours

Answer

12 hours

Answer

10 days

Question 6

Which of the following drug classes has both anti-arrhythmic and anti-anginal properties?

Accepted Answer

Beta blockers

Answer

Nitrates

Answer

Rho kinase inhibitor

Answer

Potassium channel openers

Question 7

Pulmonary fibrosis occurs most commonly due to which of the following drugs?

Accepted Answer

Amiodarone

Answer

Clindamycin

Answer

Nikkomycin

Answer

Kanamycin

Question 8

Which one of the following is not an adverse effect of ACE inhibitors?

Accepted Answer

Hypokalemia

Answer

Cough

Answer

Angioneurotic edema

Answer

Skin rash

Question 9

Which drug is used in the management of AV block?

Accepted Answer

Isoprenaline

Answer

Dopamine

Answer

Atropine

Answer

Disopyramide

Question 10

In shock, what effect does dopamine, in renal doses, have on renal vasculature?

Accepted Answer

Dilatation of renal vasculature

Answer

Reduction in peripheral resistance

Answer

Constriction of renal vasculature

Answer

Increase in cardiac output

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?